QNRX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 3.70%

Insider Buying (Last 12 Months): $32,306.38

Insider Selling (Last 12 Months): $216.81

Quoin Pharmaceuticals Insider Trading History Chart

Quoin Pharmaceuticals Share Price & Price History

^$0.78

▼ -0.0201 (-2.51%)

As of 12/9/2024 07:08 PM ET

Days: 30 | 90 | 365

This company will win the AI race

From Porter & Company | Ad

Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

Quoin Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/9/2024	Gordon Dunn	CFO	Buy	8,856	$0.79	$6,996.24	8,856
9/4/2024	Denise P Carter	COO	Buy	31,813	$0.78	$24,814.14	47,092
9/3/2024	Michael Myers	CEO	Buy	800	$0.62	$496.00	10,158
6/7/2024	Dennis Langer	Director	Sell	297	$0.73	$216.81	53

I was wrong. Dead wrong.

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

SEC Filings (Institutional Ownership Changes) for Quoin Pharmaceuticals (NASDAQ:QNRX)

8.63% of Quoin Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Quoin Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/20/2024	Virtu Financial LLC	30,749	$29K	0.0%	N/A	0.773%
5/1/2023	Virtu Financial LLC	147,907	$70K	0.0%	N/A	3.050%
11/7/2022	Virtu Financial LLC	29,865	$67K	0.0%	N/A	2.948%

Data available starting January 2016

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

Today's Range

Now: $0.78

$0.78

$0.87

50 Day Range

MA: $0.66

$0.48

$0.88

52 Week Range

Now: $0.78

$0.48

$6.18

Volume

576,841 shs

Average Volume

1,087,174 shs

Market Capitalization

$3.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.79

Who are the company insiders with the largest holdings of Quoin Pharmaceuticals?: Quoin Pharmaceuticals' top insider investors include:
Denise P Carter (COO)
Michael Myers (CEO)
Gordon Dunn (CFO)
Dennis Langer (Director)
Learn More about top insider investors at Quoin Pharmaceuticals.